Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford scientists have for the first time been able to identify the origins of some severe disease-causing mutations within the testicles of normal men.

Image courtesy of Shutterstock

This discovery will help our understanding of how certain serious genetic disorders can occur in the offspring of healthy parents, who do not themselves have the genetic defect. The research is published in the journal PNAS.

For the Oxford team, it is just the latest phase in a research programme that has been running for over 20 years. In the 1990s Professor Andrew Wilkie and colleagues were investigating a condition called Apert syndrome that affects the development of the skull and limbs. Most children with Apert syndrome are born to unaffected parents and Professor Wilkie's team showed that these cases are caused by new mutations (in a gene called FGFR2) that spontaneously arose as the father’s testes produced new sperm. Based on the prevailing knowledge of how spontaneous mutations arise, we would expect Apert syndrome to be extremely rare, but surprisingly cases occur up to 1,000 times more frequently than this.

Read more

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.

Oxford-led technology to help those at high risk from Covid-19

Coronavirus COVID-19 General Research

More people in England at high risk from Covid-19 will get priority access to vaccines thanks to new technology developed by a University of Oxford-led team of researchers that can identify those who may be most vulnerable to the virus.